We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. AnaptysBio, Inc. (ANAB - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
AnaptysBio, Inc. is a member of our Medical group, which includes 884 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AnaptysBio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ANAB's full-year earnings has moved 58.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ANAB has returned about 23.9% since the start of the calendar year. At the same time, Medical stocks have lost an average of 6.5%. This means that AnaptysBio, Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Electromed, Inc. (ELMD - Free Report) . The stock has returned 29.6% year-to-date.
In Electromed, Inc.'s case, the consensus EPS estimate for the current year increased 9.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, AnaptysBio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 430 individual companies and currently sits at #99 in the Zacks Industry Rank. This group has lost an average of 1.1% so far this year, so ANAB is performing better in this area.
In contrast, Electromed, Inc. falls under the Medical - Instruments industry. Currently, this industry has 77 stocks and is ranked #134. Since the beginning of the year, the industry has moved -16.6%.
Going forward, investors interested in Medical stocks should continue to pay close attention to AnaptysBio, Inc. and Electromed, Inc. as they could maintain their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. AnaptysBio, Inc. (ANAB - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
AnaptysBio, Inc. is a member of our Medical group, which includes 884 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AnaptysBio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ANAB's full-year earnings has moved 58.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ANAB has returned about 23.9% since the start of the calendar year. At the same time, Medical stocks have lost an average of 6.5%. This means that AnaptysBio, Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Electromed, Inc. (ELMD - Free Report) . The stock has returned 29.6% year-to-date.
In Electromed, Inc.'s case, the consensus EPS estimate for the current year increased 9.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, AnaptysBio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 430 individual companies and currently sits at #99 in the Zacks Industry Rank. This group has lost an average of 1.1% so far this year, so ANAB is performing better in this area.
In contrast, Electromed, Inc. falls under the Medical - Instruments industry. Currently, this industry has 77 stocks and is ranked #134. Since the beginning of the year, the industry has moved -16.6%.
Going forward, investors interested in Medical stocks should continue to pay close attention to AnaptysBio, Inc. and Electromed, Inc. as they could maintain their solid performance.